CNS Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

CNS Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 54.7% bzw. 86.4% pro Jahr prognostiziert, während der Gewinn pro Aktie um 68.5% pro Jahr wachsen soll.

Wichtige Informationen

54.7%

Wachstumsrate der Gewinne

68.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.7%
Wachstumsrate der Einnahmen	86.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

CNS Pharmaceuticals reports Q2 results

Aug 15

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

Dec 04

CNS Pharmaceuticals sinks after pricing equity offering of $10M

Dec 23

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CNSP - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-21	N/A	N/A	1
12/31/2025	N/A	-16	N/A	N/A	1
12/31/2024	N/A	-13	N/A	N/A	1
9/30/2024	N/A	-17	-14	-14	N/A
6/30/2024	N/A	-16	-11	-11	N/A
3/31/2024	N/A	-17	-13	-13	N/A
12/31/2023	N/A	-19	-14	-14	N/A
9/30/2023	N/A	-19	-14	-14	N/A
6/30/2023	N/A	-18	-12	-12	N/A
3/31/2023	N/A	-17	-12	-12	N/A
12/31/2022	N/A	-15	-11	-11	N/A
9/30/2022	N/A	-13	-11	-11	N/A
6/30/2022	N/A	-14	-12	-12	N/A
3/31/2022	N/A	-14	-13	-13	N/A
12/31/2021	N/A	-14	-14	-14	N/A
9/30/2021	N/A	-14	-12	-12	N/A
6/30/2021	N/A	-12	-11	-11	N/A
3/31/2021	N/A	-11	-9	-9	N/A
12/31/2020	N/A	-9	-7	-7	N/A
9/30/2020	N/A	-9	-8	-8	N/A
6/30/2020	N/A	-8	-7	-7	N/A
3/31/2020	N/A	-6	-5	-5	N/A
12/31/2019	N/A	-4	-4	-4	N/A
9/30/2019	N/A	-8	-1	-1	N/A
6/30/2019	N/A	-7	-1	-1	N/A
3/31/2019	N/A	-7	-1	-1	N/A
12/31/2018	N/A	-7	-1	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CNSP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CNSP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CNSP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CNSP wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: CNSP wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CNSP in 3 Jahren voraussichtlich hoch sein wird

CNS Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased to US$10.00

Recent updates

CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million.

The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. announced a financing transaction

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3725 million.

New major risk - Share price stability

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq

CNS Pharmaceuticals Provides Non-Compliance Update

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

New major risk - Negative shareholders equity

CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland

Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (Gbm)

CNS Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement Pursuant to Nasdaq’s Listing Rule 5550(b)(1)

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Investigator-Initiated Phase 1B/2 Trial to Be Conducted At the Pomeranian Medical University in Poland

Cns Pharmaceuticals, Inc. Appoints Faith Charles as Independent Member and as Chairperson of the Board of Directors

CNS Pharmaceuticals, Inc Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Insufficient new directors

CNS Pharmaceuticals, Inc. Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Provides A Clinical Update of Its Anti-Cancer Drug Candidates Currently in Development for the Treatment of Primary and Metastatic Brain and CNS Cancer

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2022

CNS Pharmaceuticals Inc. Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Price target increased to US$10.00

Insufficient new directors

CNS Pharmaceuticals, Inc. Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals, Inc. announced that it expects to receive $11.500001 million in funding

Insufficient new directors

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

CNS Pharmaceuticals, Inc. Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

FDA Grants Fast Track Designation to CNS Pharmaceuticals, Inc. for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals Berubicin Trial is on Schedule to Commence in March 2021

WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announces Berubicin Supply Agreement for the Upcoming Clinical Trials

WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

New 90-day high: US$3.50

CNS Pharmaceuticals Announces It Has Been Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application

CNS Pharmaceuticals sinks after pricing equity offering of $10M

CNS Pharmaceuticals, Inc. Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

New 90-day high: US$2.89

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken